- Country: USA
- Summary: Cytopathology & Thyrosequence Testing Service
- UST Ref No: 75880411
- Deadline: 07 Jan 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 36C24223Q0167
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
NOTICE OF INTENT. The Department of Veterans Affairs, Network Contracting Office 2 intends to solicit and award a sole-source, firm-fixed-price, Indefinite Delivery Contract (with individual task orders issued for the annual ordering periods) with Cytopath Biopsy Lab, Inc. (760 Westchester Ave., Rye Brook, NY 10573-1341) in accordance with 41 U.S.C. § 1901, as implemented by FAR 13.106(b)(2)(i): Only one responsible source and no other supplies or services will satisfy agency requirements. The contract anticipated effective date is January 3, 2023, for one year with four option years.This contract is for Cytopathology & Thyrosequence Testing Service. Contractor shall provide for the New York Harbor Healthcare System at Brooklyn VA Medical Center, 800 Poly place, Brooklyn NY, 11209 approximately 180 tests per year. Patient samples obtained through fine needle aspirate (FNA) biopsies are collected for both cytopathology assessment and ThyroSeq(r) GC. Initially cytopathology assessment is conducted. If the sample is read out as benign, or non-diagnostic, the sample is not sent out for genetic analysis, however if it is read as Bethesda III, IV, or V, ThyroSeq(r) GC Next Generation gene sequencing is performed. ThyroSeq(r) Genomic Classifier (GC) test utilizes next-generation sequencing to analyze DNA and RNA of 112 thyroid-related genes for four main classes of molecular alterations, including mutations, gene fusions, copy number alterations, and gene expression alterations. The results are processed by a unique Genomic Classifier (GC) and reported as Positive or Negative. As we move forward with targeted therapies, samples which are Bethesda VI (papillary carcinoma), or other thyroid cancers will also be sent for further testing.The NAICS code is 621511 (Medical Laboratories) with a small business size standard of $36.5 Million.This is for informational purposes only and is not construed as a commitment by the Government. This is not a request for offers... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINCytopathology & Thyrosequence Testing Service - USA Tender
The VETERANS AFFAIRS, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Cytopathology & Thyrosequence Testing Service. This tender is published on USARFP under UST Ref No: 75880411 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-01-07.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
